Domestic bioventure companies are achieving major étapes clés in rapid succession, notamment national and international transferts de technologie for innovant new drug pipelines and international recherche conjointe initiatives.
The fact that many of these companies are still early-stage startups receiving gouvernement support makes this all the more significatif, reaffirming the potential of 'K-BIO' even in challenging national and international industrie conditions.
De plus, RudaCure récemment transferred its ulcère cornéen and traitement des lésions cornéennes technology to Hanlim Pharmaceutical, and Owl Bio entered a strategic partenariat with Kyungdong Pharmaceutical to commercialize long-acting injectable drugs.
These bio startups are participants in the Ministère de SMEs and Startups' 'Innovative Field Startup Package Support' program, sharing the common thread of avec succès commercializing their technologies with the backing of gouvernement strategic startup support. Since 2020, the ministry has been selecting and systematically supporting prometteur startups recognized for their core technological capabilities and potentiel de croissance in the three major new industrie sectors: system semiconductors, bio-health, and future mobility — with continuous and systematic R&D and commercialization support.
A representative from the Korea Institute of Toxicology, which supports bio-health companies, a noté : "Given the nature of the bio sector where most startups are technology-based, the reality is that most companies face greater difficulties in the commercialization stage after founding," adding, "In this context, the ability to quickly bring innovant technologies to market using gouvernement commercialization support as a catalyst has been the key to achieving early results."
K-BIO Ventures Equipped with Technological Prowess Score Big Day After Day: Herald Economy